Figure 8 — Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Research Paper|Volume 16, Issue 6|pp. 5618–5633

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Back to articleFigure 8(8 of 8)

100%

Figure 8.Drug sensitivity analysis for high-risk TERTp-mutant gliomas. (A–C) OncoPredict analysis of drug sensitivity of TERTp-mutant gliomas. Results suggest higher sensitivity to 5-fluorouracil and gemcitabine therapies for glioma patients in the high- vs. the low-risk group. ^***P < 0.001.